The current management structure of the SwaLife Biotech has two founder members. Duties and roles have been shared based on individual abilities and expertise. The CEO of the company will be Dr Pravin Badhe while Mr Basudev Paudyal will take CSO responsibilities.

Dr. Pravin Badhe (Founder/CEO):

has over 12 years of experience in Pharmaceutical field. He has expertise in target discovery and lead identification and has experience in drug repurposing in rare disease such as progeria. He is a Pharmacist and has PhD in life science. In PhD he has discover five novel small molecules from plants. He is an experience scientist and has got expertise in pharma wholesale, retail sales, marketing and general management. He has held number of positions with both research and development. As research assistant, he led cross-functional teams in the delivery of standardise plant extracts and fractions for cosmetic purpose.

He is founder and CEO of Swalife Biotech and is responsible for developing and managing financial systems and policies. He is responsible in recruiting, communicating values and developing education opportunities. He will represent the company in strategic meetings and will be responsible for preparing financial reports, budgets, and financial statements for the organization. He is advisor in Shree Om Medico pharma distributor company in India. He brings extensive experience of growing organisations across all aspects of the biotech environment.

Mr Basudev Paudyal (Co-founder)/CSO):

He is the co-founder of SwaLife Biotech. He has completed his BSc (Hons) Microbiology from University of West of England in 2009 and MSc Cancer Biology (2012) from Kingston University London and currently in the final year of his PhD in nanoparticles and their immune response from Kinston University London. He is responsible for research and development in collaboration with others on projects. He makes detailed observations, analyses data and interprets results. Basudev will also prepare technical reports, summaries, protocols, and quantitative analyses. An incumbent maintains familiarity with current scientific literature and contributes to the process of a project within his scientific discipline, as well as investigating, creating, and developing new methods and technologies for project advancement.

The majority of new medicinal compounds developed for the treatment of cancer fail during the course of their development and pharmaceutical companies have moved in recent years to broadening the modalities and the range of sources from which potential compounds can be identified. As a result of this, there is opportunity for small biotech companies to develop leads for eventual sale to or partnering with pharmaceutical companies. This is particularly the case for novel drug discovery modalities or for biological targets that have proved untreatable by conventional drug discovery methodologies. One such area is the deployment of alkaloid molecules.


Scientific Advisory Body


=> Dr Ian Kill: Brunel University

=> Dr Joanna Bridger: Brunel University

=> Dr Svetlana Ignatova: Brunel University

=> Prof. Juliette Legler: Brunel University


Business Advisory Body


=> Andrew Foxley: Senior Director Scientific Project Management, AstraZeneca

=> Bil Lio: SOSV investment Partner